Biological effects of mutant ceruloplasmin on hepcidin-mediated internalization of ferroportin.
Ceruloplasmin plays an essential role in cellular iron efflux by oxidizing ferrous iron exported from ferroportin. Ferroportin is posttranslationally regulated through internalization triggered by hepcidin binding. Aceruloplasminemia is an autosomal recessive disorder of iron homeostasis resulting from mutations in the ceruloplasmin gene. The present study investigated the biological effects of glycosylphosphatidylinositol (GPI)-linked ceruloplasmin on the hepcidin-mediated internalization of ferroportin. The prevention of hepcidin-mediated ferroportin internalization was observed in the glioma cells lines expressing endogenous ceruloplasmin as well as in the cells transfected with GPI-linked ceruloplasmin under low levels of hepcidin. A decrease in the extracellular ferrous iron by an iron chelator and incubation with purified ceruloplasmin in the culture medium prevented hepcidin-mediated ferroportin internalization, while the reconstitution of apo-ceruloplasmin was not able to prevent ferroportin internalization. The effect of ceruloplasmin on the ferroportin stability was impaired due to three distinct properties of the mutant ceruloplasmin: namely, a decreased ferroxidase activity, the mislocalization in the endoplasmic reticulum, and the failure of copper incorporation into apo-ceruloplasmin. Patients with aceruloplasminemia exhibited low serum hepcidin levels and a decreased ferroportin protein expression in the liver. The in vivo findings supported the notion that under low levels of hepcidin, mutant ceruloplasmin cannot stabilize ferroportin because of a loss-of-function in the ferroxidase activity, which has been reported to play an important role in the stability of ferroportin. The properties of mutant ceruloplasmin regarding the regulation of ferroportin may therefore provide a therapeutic strategy for aceruloplasminemia patients.
Kono
Satoshi
S
First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan. satokono@hama-med.ac.jp
Yoshida
Kenichi
K
Tomosugi
Naohisa
N
Terada
Tatsuhiro
T
Hamaya
Yasushi
Y
Kanaoka
Shigeru
S
Miyajima
Hiroaki
H
D023181:Antimicrobial Cationic Peptides / Q000097:blood / Q000378:metabolism* / Q000494:pharmacology; D015153:Blotting, Western; D027682:Cation Transport Proteins / Q000378:metabolism*; D045744:Cell Line, Tumor; D002570:Ceruloplasmin / Q000235:genetics / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D004705:Endocytosis / Q000187:drug effects; D005260:Female; D020869:Gene Expression Profiling; D017261:Glycosylphosphatidylinositols / Q000378:metabolism; D006367:HeLa Cells; D064451:Hepcidins; D006801:Humans; D019189:Iron Metabolism Disorders / Q000097:blood / Q000235:genetics / Q000378:metabolism; D008099:Liver / Q000378:metabolism; D008297:Male; D009154:Mutation; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014162:Transfection; D000098742:Ferroportin
D023181:Antimicrobial Cationic Peptides; D027682:Cation Transport Proteins; D017261:Glycosylphosphatidylinositols; C578702:HAMP protein, human; D064451:Hepcidins; D000098742:Ferroportin; D002570:Ceruloplasmin